Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y 12 Inhibitor Prescribing
Clinical Pharmacology & Therapeutics · 2025-08 · 118 (2) · 470-479
DOI: 10.1002/cpt.3698 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 12.05.2025. Verfasst von Ashley N Springer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Decision Support Systems, Clinical, Purinergic P2Y Receptor Antagonists, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
P2Y 12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support ( CDS ) alerts in the electronic health record ( EHR ) to recommend alternative P2Y 12 inhibitors for patients with decreased CYP2C19 function who had undergone percutaneous coronary intervention ( PCI ). The objective of this study was to evaluate prescriber response to these CDS alerts. Utilizing alert response data and P2Y 12 inhibitor prescriptions from October 2020 to December 2023, we evaluated prescriber response for 362 patients who had a mean of 2.2 (SD: 1.7) CYP2C19 ‐clopidogrel alerts fire post‐PCI. Alert recommendations were accepted 24.5% ± 36.8% (mean ± SD) of the time. Alternative (i.e., non‐clopidogrel) P2Y 12 inhibitors were prescribed for 22.4% ± 36.8% of days during the year following PCI. Alerts were accepted more for CYP2C19 poor metabolizers than for intermediate metabolizers ( P = 0.03). Each year after 2020 was associated with a 4.6% increase in the days prescribed alternative P2Y 12 inhibitors. In contrast, increasing age was associated with decreased alert acceptance and decreased percentage of days prescribed alternatives, and concomitant oral anticoagulant use was associated with decreased percentage of days prescribed alternatives. Provider clinical judgment was the most common alert override reason, accounting for 68% of clinician responses. Our findings demonstrate that CYP2C19 ‐clopidogrel CDS alerts promoted genotype‐guided P2Y 12 inhibitor prescribing in some cases (~22% of study days). Future research should better determine prescriber reasons for rejecting alert recommendations and establish best implementation practices to complement CDS alerts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Division of Diagnostic Genetics and Genomics, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Agena Bioscience, San Diego, California, USA.
- Division of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Indiana University Health, Indianapolis, Indiana, USA.
ORCID-Profile: Ashley N Springer, Jennelle C Hodge, Victoria M Pratt, Michael T Eadon, Emma M Tillman, Tyler Shugg, Todd C Skaar
Förderung
- NIGMS NIH HHS
Zitieren
APA
Springer, A. N., Alicea, L. A., Gafari, Y., Smith, T. B., Lynch, S., Breman, A. M., Hodge, J. C., Pratt, V. M., Powell, N. R., Kreutz, R. P., Kobold, D. P., Eadon, M. T., Tillman, E. M., Shugg, T., & Skaar, T. C. (2025). Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y 12 Inhibitor Prescribing. Clinical Pharmacology & Therapeutics, 118(2), 470-479. https://doi.org/10.1002/cpt.3698
Vancouver
Springer AN, Alicea LA, Gafari Y, Smith TB, Lynch S, Breman AM, et al. Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y 12 Inhibitor Prescribing. Clinical Pharmacology & Therapeutics. 2025;118(2):470-479. doi:10.1002/cpt.3698
BibTeX
@article{Springer2025,
author = {Springer, Ashley N and Alicea, Leah A and Gafari, Yemi and Smith, Tayler B and Lynch, Sheryl and Breman, Amy M and Hodge, Jennelle C and Pratt, Victoria M and Powell, Nicholas R and Kreutz, Rolf P and Kobold, Daniel P and Eadon, Michael T and Tillman, Emma M and Shugg, Tyler and Skaar, Todd C},
title = {Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y 12 Inhibitor Prescribing},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {118},
number = {2},
pages = {470--479},
doi = {10.1002/cpt.3698}
}
EUVIMED